Steroidogenesis Inhibitors Receives Final Payment for Licensing ANTICORT to Altachem-Pharma, Canada

LAS VEGAS (April 15) BW HEALTHWIRE -April 15, 1999--

Altachem to Commence Clinical Study With ANTICORT(TM)

Steroidogenesis Inhibitors International (OTCBB:STGI) today announced that it has received $50,000 from Altachem-Pharma, (Alberta Stock Exchange: AAF) representing the last installment on the $300,000 licensing fees for ANTICORT(TM) in Canada.

Altachem-Pharma announced they have received approval from the Health Protection Bureau (HPB), the Canadian equivalent of the U.S. FDA, and will begin a Phase 1 clinical study of ANTICORT in HIV positive patients receiving anti-HIV treatment. The study in Canada is the third testing of Anticort following clinical studies in the U.S. and Romania in HIV positive children.

STGI is a pharmaceutical R&D Corporation, engaged in the development of anticortisol drugs to be used in diseases/conditions associated with elevated levels of the immunosuppressive hormone cortisol. STGI's flagship anticortisol drug, ANTICORT, has been approved by the FDA to be clinically tested in an HIV population - a condition often associated with "high cortisol" that is apparently playing a major role in the destruction of the immune system as encountered in HIV+ and AIDS. This release may include "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com.

-0- emb/ny*

CONTACT:  STEROIDOGENESIS           PERFORMANCE STRATEGIES 
           Janet Greeson, Ph.D.      Richard L. Brown/Chuck Jordan 

(702) 735-7001            (303) 471-5943 

H.L. LANZET INC.

           Herbert Lanzet/DeeDee Lanzet 

(212) 687-0061

KEYWORD: NEVADA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL Today's News On The
Net - Business Wire's full file on the Internet

with Hyperlinks to your home page.

                      URL: http://www.businesswire.com